Compare ARK Genomic Revolution ETF (ARKG) vs Barclays PLC (BCS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Barclays PLC — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Barclays PLC trades at $27.18 (market cap $91.26B). The key difference: Barclays PLC pays a 1.67% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | BCS | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $28.41 |
52-Week Low | $23.09 | $18.40 |
Market Cap | — | $91.26B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Barclays PLC (BCS) trades at $27.48, up 0.88% today, near its 52-week high of $28.43. The stock shows a bullish technical trend with strong moving average signals. Fundamentally, revenue grew to $29.14B in 2025 with a robust net income margin of 24.5%, while the P/E ratio of 11.99 suggests reasonable valuation. Recent earnings beats and positive analyst sentiment support the uptrend.
The outlook remains positive given consistent earnings outperformance and Wall Street's bullish stance, though risks include ongoing legal investigations and volatile cash flow patterns. Investment appeal hinges on sustained profitability and resolution of legal overhangs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →
